ArticleScientific reports2022

Cost-effectiveness of managing HBV reactivation in patients with resolved HBV infection treated with anti-CD20 antibody for B-cell non-Hodgkin lymphoma.

Misuzu Fujita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.